DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: MALARONE

Summary for Tradename: MALARONE

Patents:3
Applicants:1
NDAs:1
Suppliers: see list4
drug
patent expirations by year for
 MALARONE

Pharmacology for Tradename: MALARONE

Clinical Trials for: MALARONE

Weekly Dosing of Malarone ® for Prevention of Malaria
Status: Completed Condition: Malaria

Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Status: Active, not recruiting Condition: Malaria

Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function
Status: Completed Condition: Malaria; Falciparum

Chloroquine Alone or in Combination for Malaria in Children in Malawi
Status: Completed Condition: Plasmodium Falciparum Infection

Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
Status: Completed Condition: Malaria, Falciparum

Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites
Status: Completed Condition: Malaria, Falciparum

Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
Status: Not yet recruiting Condition: Malaria

Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
Status: Recruiting Condition: Malaria

Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
Status: Completed Condition: Malaria; Plasmodium Falciparum

Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
Status: Completed Condition: Plasmodium Falciparum Malaria

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
MALARONE
atovaquone; proguanil hydrochloride
TABLET;ORAL021078Jul 14, 2000RXYes5,998,449*PED<disabled>Y<disabled>
Glaxosmithkline
MALARONE
atovaquone; proguanil hydrochloride
TABLET;ORAL021078Jul 14, 2000RXYes6,166,046*PED<disabled>Y<disabled>
Glaxosmithkline
MALARONE
atovaquone; proguanil hydrochloride
TABLET;ORAL021078Jul 14, 2000RXYes6,291,488*PED<disabled>Y<disabled>
Glaxosmithkline
MALARONE PEDIATRIC
atovaquone; proguanil hydrochloride
TABLET;ORAL021078Jul 14, 2000RXNo5,998,449*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MALARONE

Drugname Dosage Strength RLD Submissiondate
atovaquone and proguanil hydrochlorideTablets62.5 mg/25 mgMalarone9/14/2010
atovaquone and proguanil hydrochlorideTablets250 mg/100 mgMalarone4/3/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc